Genmab stock price target raised to $32 from $24 at TD Cowen on MRUS deal

Genmab A/S is acquiring MRUS for approximately $8 billion, a strategic move to shift from a royalty-based model to developing wholly-owned products, highlighted by the acquisition of petosemtamab, a Phase 3 bispecific antibody with multi-billion dollar potential in HNSCC. This expansion is supported by Genmab's strong financial position, including 94.54% gross profit margins and more cash than debt, and recent impressive Q2 2025 results. Analysts, including TD Cowen, Leerink, and H.C. Wainwright, have raised price targets, with TD Cowen projecting the deal to become accretive by 2029.

Analysis

Genmab A/S (GMAB) is executing a significant strategic pivot with its planned $8 billion all-cash acquisition of Merus (MRUS), aimed at shifting its business from a royalty-based model to one centered on wholly-owned products. This move is supported by a robust financial position, characterized by a balance sheet holding more cash than debt and impressive gross profit margins of 94.54%. The core of the acquisition is petosemtamab, a late-stage bispecific antibody in Phase 3 trials for HNSCC, which analysts note has multi-billion dollar potential, though key data is not expected until 2026 and the deal is projected to become accretive only by 2029. The market and analysts have responded positively to the strategy, underscored by Genmab's recent strong Q2 2025 performance, where EPS beat consensus by 39.4% and revenue surpassed expectations by 3.54%. Consequently, multiple analysts, including those at TD Cowen, Leerink Partners, and H.C. Wainwright, have raised their price targets, ranging from $32 to $36, reflecting confidence in the company's pipeline and strategic direction as the stock trades near its 52-week high.

Key Decisions for Investors

• Investors should view the Merus acquisition as a long-term value driver, focusing on the 2026 clinical data readout for petosemtamab and the 2029 accretion timeline rather than expecting near-term earnings impact.
• The primary catalyst and risk factor for the acquisition's success is the outcome of the petosemtamab Phase 3 trial; this clinical milestone should be monitored closely as it will be pivotal for validating the deal's valuation.
• While strong fundamentals and positive analyst revisions support the stock's position near its 52-week high, investors should consider that much of the positive strategic news may already be reflected in the current price, warranting a disciplined approach to new or additional positions.